PROPHASE LABS INC. - COMMON STOCK

Navidea Biopharmaceuticals Rejects ProPhase Labs Offer To Acquire Certain Assets of Navidea

29 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

ProPhase Labs Inc. Sets the Course for Expansion into the MENA Region with Cutting-Edge Genomic and Diagnostics Technologies

22 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

ProPhase Labs to Present at the Diamond Equity Research Emerging Growth Invitational on Tuesday, June 13, 2023

07 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

ProPhase Labs’ Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testing

01 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2023

11 May 2023 07:00:02 By Nasdaq GlobeNewswire

ProPhase Labs hires Dr. Matthew Halpert to Drive Company’s Key Therapeutic and Diagnostic Oncology Programs

08 May 2023 07:30:00 By Nasdaq GlobeNewswire

ProPhase Labs to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 11, 2023 at 11:00 a.m. Eastern Time

04 May 2023 07:30:01 By Nasdaq GlobeNewswire

ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers

03 May 2023 07:30:00 By Nasdaq GlobeNewswire

ProPhase Labs CEO Ted Karkus Named One of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023

28 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

ProPhase Labs Announces Launch of Redesigned Corporate Website

25 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1x1 Meetings on Thursday, April 27, 2023

18 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022

28 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

ProPhase Labs to Host 2022 Year End Financial Results Conference Call on Tuesday, March 28, 2023 at 11:00 a.m. Eastern Time

21 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

ProPhase Labs Announces New $6 Million Stock Repurchase Program

15 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test 

13 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

ProPhase Labs’ Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test

07 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

ProPhase Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)

22 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science

16 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand

15 Feb 2023 07:00:00 By Nasdaq GlobeNewswire